These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7715916)

  • 1. Ocular drug safety and HMG-CoA-reductase inhibitors.
    Schmidt J; Schmitt C; Hockwin O; Paulus U; von Bergmann K
    Ophthalmic Res; 1994; 26(6):352-60. PubMed ID: 7715916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No lens changes caused by simvastatin results from a prospective drug safety study.
    Schmidt J; Schmitt C; Hockwin O
    Lens Eye Toxic Res; 1990; 7(3-4):643-50. PubMed ID: 2100182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The HMG-CoA reductase inhibitors simvastatin and pravastatin. No indication for side effects in use on humans].
    Schmidt J; Schmitt C; Hockwin O
    Fortschr Ophthalmol; 1991; 88(6):843-5. PubMed ID: 1794817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular drug-safety study with the HMG-CoA reductase inhibitor pravastatin.
    Schmitt C; Schmidt J; Hockwin O
    Lens Eye Toxic Res; 1990; 7(3-4):631-42. PubMed ID: 2129220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin and the human lens. Clinical results of a 3-year follow-up.
    Behrens-Baumann W; Thiery J; Wieland E; Fieseler HG; Seidel D
    Arzneimittelforschung; 1992 Aug; 42(8):1023-4. PubMed ID: 1418074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term clinical tolerance of lovastatin and simvastatin.
    Bilheimer DW
    Cardiology; 1990; 77 Suppl 4():58-65. PubMed ID: 2073673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Simvastatin in the treatment of hypercholesterolemia].
    Cigala O; Pancallo MT; Della Valle M; Marasco A; Malarbi AL
    Clin Ter; 1991 Jun; 137(5):333-7. PubMed ID: 1832606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants.
    Farmer JA; Washington LC; Jones PH; Shapiro DR; Gotto AM; Mantell G
    Clin Ther; 1992; 14(5):708-17. PubMed ID: 1468089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis].
    Giannini SD; de Góes JM; Dereviack BE; Machado C; Forti N; Diament J
    Arq Bras Cardiol; 1990 Jun; 54(6):407-14. PubMed ID: 2288531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lovastatin and the human lens; results of a two year study. The MSDRL Study Group.
    Chylack LT; Mantell G; Wolfe JK; Friend J; Rosner B
    Optom Vis Sci; 1993 Nov; 70(11):937-43. PubMed ID: 8302530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The efficacy and tolerance of simvastatin and fenofibrate in primary hypercholesterolemia].
    Fricker J; Douste-Blazy P; Drouin P; De Gennes JL; Dachet C; Keller U
    Presse Med; 1990 Dec; 19(42):1927-30. PubMed ID: 2147752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus.
    Sartor G; Katzman P; Eizyk E; Kalén J; Nilsson A; Ugander L; Ursing D
    Int J Clin Pharmacol Ther; 1995 Jan; 33(1):3-6. PubMed ID: 7711988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and efficacy of simvastatin and fenofibrate--a multicenter study. Simvastatin-Fenofibrate Study Group.
    Ziegler O; Drouin P
    Cardiology; 1990; 77 Suppl 4():50-7. PubMed ID: 2073672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical efficacy and safety of lovastatin and MK-733--an overview.
    Walker JF; Tobert JA
    Eur Heart J; 1987 Aug; 8 Suppl E():93-6. PubMed ID: 3315683
    [No Abstract]   [Full Text] [Related]  

  • 18. Pravastatin, simvastatin, and lovastatin for lowering serum cholesterol concentrations.
    Med Lett Drugs Ther; 1992 Jun; 34(872):57-8. PubMed ID: 1593973
    [No Abstract]   [Full Text] [Related]  

  • 19. HMG CoA reductase inhibitors in the treatment of hypercholesterolaemias.
    Aronson JK; Ng LL
    Q J Med; 1990 Feb; 74(274):111-5. PubMed ID: 2111916
    [No Abstract]   [Full Text] [Related]  

  • 20. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
    Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
    Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.